A retrospective clinical research study assessing PD-1 inhibitors combined with apatinib for advanced diffuse gastric cancer
Latest Information Update: 05 Jul 2022
At a glance
- Drugs Programmed cell death 1 receptor antagonists (Primary) ; Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology